2024/03/22 更新

写真a

タカノ ナオ
高野 奈緒
TAKANO Nao
所属
医学部附属病院 先端医療開発部 先端医療・臨床研究支援センター 病院講師
職名
病院講師

学位 1

  1. 医学博士 ( 2017年3月   名古屋大学 ) 

経歴 2

  1. 名古屋大学   医学部附属病院 先端医療開発部 先端医療・臨床研究支援センター   病院講師

    2023年10月 - 現在

  2. 医薬品医療機器総合機構   新薬審査第五部   審査専門員   審査専門員

    2019年10月 - 2023年9月

 

論文 44

  1. Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022 (oct, 10.1007/s10157-023-02415-0, 2022)

    Yanagita, M; Muto, S; Nishiyama, H; Ando, Y; Hirata, S; Doi, K; Fujiwara, Y; Hanafusa, N; Hatta, T; Hoshino, J; Ichioka, S; Inoue, T; Ishikura, K; Kato, T; Kitamura, H; Kobayashi, Y; Koizumi, Y; Kondoh, C; Matsubara, T; Matsubara, K; Matsumoto, K; Okuda, Y; Okumura, Y; Sakaida, E; Shibagaki, Y; Shimodaira, H; Takano, N; Uchida, A; Yakushijin, K; Yamamoto, T; Yamamoto, K; Yasuda, Y; Oya, M; Okada, H; Nangaku, M; Kashihara, N

    CLINICAL AND EXPERIMENTAL NEPHROLOGY   28 巻 ( 2 ) 頁: 123 - 124   2024年2月

  2. Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

    Ando Yuichi, Nishiyama Hiroyuki, Shimodaira Hideki, Takano Nao, Sakaida Emiko, Matsumoto Koji, Nakanishi Koki, Sakai Hideki, Tsukamoto Shokichi, Komine Keigo, Yasuda Yoshinari, Kato Taigo, Fujiwara Yutaka, Koyama Takafumi, Kitamura Hiroshi, Kuwabara Takashige, Yonezawa Atsushi, Okumura Yuta, Yakushijin Kimikazu, Nozawa Kazuki, Goto Hideaki, Matsubara Takeshi, Hoshino Junichi, Yanagita Motoko

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   28 巻 ( 10 ) 頁: 1315 - 1332   2023年10月

     詳細を見る

    記述言語:英語   出版者・発行元:International Journal of Clinical Oncology  

    Cisplatin should be administered with diuretics and Magnesium supplementation under adequate hydration to avoid renal impairment. Patients should be evaluated for eGFR (estimated glomerular filtration rate) during the treatment with pemetrexed, as kidney injury has been reported. Pemetrexed should be administered with caution in patients with a CCr (creatinine clearance) < 45 mL/min. Mesna is used to prevent hemorrhagic cystitis in patients receiving ifosfamide. Febuxostat is effective in avoiding hyperuricemia induced by TLS (tumor lysis syndrome). Preventative rasburicase is recommended in high-risk cases of TLS. Thrombotic microangiopathy could be triggered by anticancer drugs and there is no evidence of efficacy of plasma exchange therapy. When proteinuria occurs during treatment with anti-angiogenic agents or multi-kinase inhibitors, dose reductions or interruptions based on grading should be considered. Grade 3 proteinuria and renal dysfunction require urgent intervention, including drug interruption or withdrawal, and referral to a nephrologist should be considered. The first-line drugs used for blood pressure elevation due to anti-angiogenic agents are ACE (angiotensin-converting enzyme) inhibitors and ARBs (angiotensin receptor blockers). The protein binding of drugs and their pharmacokinetics are considerably altered in patients with hypoalbuminemia. The clearance of rituximab is increased in patients with proteinuria, and the correlation with urinary IgG suggests similar pharmacokinetic changes when using other antibody drugs. AIN (acute interstitial nephritis) is the most common cause of ICI (immune checkpoint inhibitor)-related kidney injury that is often treated with steroids. The need for renal biopsy in patients with kidney injury that occurs during treatment with ICI remains controversial.

    DOI: 10.1007/s10147-023-02382-2

    Web of Science

    Scopus

    PubMed

  3. Conversion surgeryを行った門脈腫瘍栓を伴う切除不能胃癌の1例

    杉山 史剛, 高野 奈緒, 桑野 誠也, 野々垣 郁絵, 堀田 佳宏, 日比 健志

    日本臨床外科学会雑誌   83 巻 ( 2 ) 頁: 326 - 330   2022年

     詳細を見る

    記述言語:日本語   出版者・発行元:日本臨床外科学会  

    <p>症例は80歳,男性.悪寒と上腹部痛を主訴に当院へ搬送され,門脈腫瘍栓・多発リンパ節転移を伴う進行胃癌,腫瘍の胆管圧排による急性胆管炎と診断された.根治切除は困難であると判断し,胆管炎治療後に化学療法を導入した.HER2陽性であり,Cape+OHP+T-mabを計13コース施行し,門脈腫瘍栓の消失,原発巣の著明な縮小を認めたため,D2郭清を伴う胃全摘術を施行した.病理組織学的所見はypT3 N2 (3/24) CY0 ypStage IIIA,化学療法の組織学的効果判定はGrade 1aであった.術後補助化学療法としてS-1を8カ月間内服し,現在術後36カ月無再発生存が得られている.</p>

    DOI: 10.3919/jjsa.83.326

    CiNii Research

  4. Association between working overtime and psychological stress reactions in elementary and junior high school teachers in Japan: a large-scale cross-sectional study

    Furihata Rika, Kuwabara Miki, Oba Koji, Watanabe Kazuhiro, Takano Nao, Nagamine Noritoshi, Maruyama Yoko, Ito Nobuhiro, Watanabe Izumi, Tsubono Kenjiro, Ikeda Chikako, Sakamoto Junichi

    Industrial health   60 巻 ( 2 ) 頁: 133 - 145   2021年10月

     詳細を見る

    記述言語:英語   出版者・発行元:独立行政法人 労働者健康安全機構 労働安全衛生総合研究所  

    This study aimed to investigate the relationship between working overtime and psychological stress reactions among school teachers. It also evaluated the interaction of overtime work types (on weekdays, on holidays, and bringing work home) and task content (educational, peripheral and both). This cross-sectional study was conducted on Japanese elementary and junior high school teachers. Primary outcome was psychological stress reactions measured with the Brief Job Stress Questionnaire. Participants were asked how long they work overtime on weekdays, holidays, and at home. Participants were also asked whether they engaged in educational tasks and/ or peripheral tasks during that overtime work. Multiple linear regression analyses were applied and 6,135 participants were included in the analyses after imputing missing data. Working hours of all three types were significantly correlated with higher psychological stress reactions. Moreover, engaging in both educational and peripheral tasks showed higher psychological stress reactions than in only educational tasks when working overtime on weekdays and holidays. In conclusion, reducing overtime work regardless of work types is crucial for mitigating psychological stress reactions for teachers. It might also be possible to manage the psychological stress reactions by splitting the role of task contents, when working overtime on weekdays and holidays at school.

    DOI: 10.2486/indhealth.2021-0069

    Web of Science

    Scopus

    PubMed

    CiNii Research

  5. The impact of early tumor shrinkage on conversion surgery and the survival in patients with unresectable locally advanced pancreatic cancer

    Takano Nao, Yamada Suguru, Sonohara Fuminori, Inokawa Yoshikuni, Takami Hideki, Hayashi Masamichi, Koike Masahiko, Fujii Tsutomu, Kodera Yasuhiro

    SURGERY TODAY   51 巻 ( 7 ) 頁: 1099 - 1107   2021年7月

     詳細を見る

    記述言語:英語   出版者・発行元:Surgery Today  

    Purposes: Owing to recent advances in induction chemo(radio)therapy, patients with unresectable locally advanced pancreatic ductal adenocarcinoma (UR-LA PDAC) are sometimes indicated for conversion surgery (CS). However, the predictors for proceeding to CS are unclear. We investigated the predictive factors for CS, especially at the early stage of induction therapy, and evaluated the impact of CS on the survival. Methods: We analyzed 49 UR-LA PDAC patients retrospectively and investigated the predictive factors for proceeding to CS, including early tumor shrinkage (ETS). ETS in this study was defined as shrinkage of tumors by ≥ 15% at 8–12 weeks after the induction of treatment. Results: CS was performed in 21 patients (43%). In a multivariate logistic regression analysis, ETS was an independent predictive factor for successfully proceeding to CS (P = 0.046). The median overall survival (OS) was not reached in the CS group but was 17.2 months in the non-CS group (P < 0.0001). A multivariate analysis by the Cox proportional hazard model identified CS as the only significant independent determinant of the OS (hazard ratio: 0.26, 95% confidence interval: 0.07–0.94, P = 0.004). Conclusions: ETS by induction therapy is a significant predictor of proceeding to CS among patients with UR-LA PDAC. CS was the only independent prognostic factor for this population.

    DOI: 10.1007/s00595-020-02220-2

    Web of Science

    Scopus

    PubMed

  6. An exploratory questionnaire survey about overwork on mental health of Japanese elementary and junior high school teachers

    Kuwabara Miki, Oba Koji, Takano Nao, Nagamine Noritoshi, Maruyama Yoko, Ito Nobuhiro, Watanabe Izumi, Ikeda Chikako, Sakamoto Junichi

    JOURNAL OF MENTAL HEALTH TRAINING EDUCATION AND PRACTICE   16 巻 ( 3 ) 頁: 181 - 186   2021年5月

     詳細を見る

    出版者・発行元:Journal of Mental Health Training, Education and Practice  

    Purpose: Occupational stress-relating overwork among teachers predispose to mental disorders and eventually lead to long leave from work. Although some studies have been conducted to assess these problems among elementary and junior high school teachers, a quantitative investigation has been limited to date. In this study, the authors sought to explore the association between overwork and mental stress among Japanese elementary and junior high school teachers. Design/methodology/approach: An exploratory cross-sectional questionnaire survey was carried out on 294 Japanese elementary and junior high school teachers. The respondents filled a questionnaire on personal data, and occupational stress reaction was evaluated by Japanese version of Brief Job Questionnaire. Multiple linear regression model was used to evaluate the association between overwork information and psychological and physical stress. Findings: Working during holidays was significantly likely to increase psychological and physical stress reactions among elementary school teachers (adjusted mean difference = −1.67, 95% CI: −2.81 to −0.54) and junior high school teachers (adjusted mean difference = −5.24, 95% CI: −9.60 to −0.87). A weakly positive association was found between high risk of psychological and physical stress and marital status (p = 0.005), teacher in charge of class (p = 0.015) among elementary school teachers. Originality/value: This study indicated an association between working during holidays and psychological and physical stress reactions among elementary and junior high school teachers after adjusting for sociodemographic and work-related status. Further study for the confirmation of this finding is warranted.

    DOI: 10.1108/JMHTEP-01-2020-0002

    Web of Science

    Scopus

  7. Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study)

    Nakayama Goro, Takano Nao, Taniguchi Hiroya, Ishigure Kiyoshi, Yokoyama Hiroyuki, Teramoto Hitoshi, Hashimoto Ryoji, Sakai Mitsuru, Ishiyama Akiharu, Kinoshita Takashi, Hayashi Naomi, Nakamura Masanori, Hattori Norifumi, Sato Yusuke, Umeda Shinichi, Uehara Kei, Aiba Toshisada, Sonohara Fuminori, Hayashi Masamichi, Kanda Mitsuro, Kobayashi Daisuke, Tanaka Chie, Yamada Suguru, Koike Masahiko, Fujiwara Michitaka, Murotani Kenta, Ando Masahiko, Ando Yuichi, Muro Kei, Kodera Yasuhiro

    EUROPEAN JOURNAL OF CANCER   144 巻   頁: 61 - 71   2021年2月

     詳細を見る

    記述言語:英語   出版者・発行元:European Journal of Cancer  

    Background: Peripheral sensory neuropathy (PSN) caused by oxaliplatin-based adjuvant chemotherapy adversely affects patients' quality of life. This study evaluated the efficacy and safety of capecitabine plus oxaliplatin (CAPOX) with intermittent oxaliplatin use compared with the standard CAPOX in adjuvant therapy for colon cancer. Patients and methods: Patients with curative resection for stage II/III colon cancer were randomly assigned to receive either CAPOX with continuous oxaliplatin (eight cycles of CAPOX) or CAPOX with intermittent oxaliplatin (two cycles of CAPOX, four cycles of capecitabine and two cycles of CAPOX). The primary end-point was the 1-year PSN rate, and the key secondary end-point was disease-free survival (DFS). Results: Two hundred patients were enrolled in the intent-to-treat population. After 4 patients withdrew, 196 patients were included in the safety analysis. The overall treatment completion rate was 65% for continuous vs. 89% for intermittent treatment (p < 0.001). The 1-year PSN rate was 60% (95% confidence interval [CI], 50%–70%) for continuous and 16% (95% CI, 10%–25%) for intermittent treatment (p < 0.001). After a median follow-up of 52 months, 40 events (20%) were observed. The 3-year DFS was 81% (95% CI, 71%–87%) for continuous and 84% (95% CI, 75%–90%) for intermittent treatment (hazard ratio [HR], 0.87; 95% CI, 0.47–1.63). Among patients with high-risk disease (T4 or N2-3), the 3-year DFS was 57% for continuous vs. 74% for intermittent treatment (HR, 0.66). Conclusion: CAPOX with planned intermittent oxaliplatin may be feasible as an adjuvant therapy for colon cancer and substantially reduce the duration of long-lasting PSN. Trial identifier: UMIN000012535.

    DOI: 10.1016/j.ejca.2020.11.007

    Web of Science

    Scopus

    PubMed

  8. Different Characteristics of Serum Alfa Fetoprotein and Serum Des-gamma-carboxy Prothrombin in Resected Hepatocellular Carcinoma

    Hayashi Masamichi, Yamada Suguru, Takano Nao, Okamura Yukiyasu, Takami Hideki, Inokawa Yoshikuni, Sonohara Fuminori, Tanaka Nobutake, Shimizu Dai, Hattori Norifumi, Kanda Mitsuro, Tanaka Chie, Nakayama Goro, Koike Masahiko, Kodera Yasuhiro

    IN VIVO   35 巻 ( 3 ) 頁: 1749 - 1760   2021年

     詳細を見る

    記述言語:英語   出版者・発行元:In Vivo  

    Background/Aim: Hepatocellular carcinoma (HCC) mainly develops in the damaged liver from hepatitis C virus (HCV) or hepatitis B virus (HBV) infection in Japan. On the other hand, the occurrence of HCCs derived from the liver without viral infection has recently been increasing. Our aim was to identify characteristics specific to HCCs with virus-infected liver (HCC-BC) or those with non-B- and non-C-infected liver (HCC-NBNC), Patients and Methods: We collected preoperative serum α-fetoprotein (AFP) and Des-Gamma-Carboxy Prothrombin (DCP), also known as PIVKA-II values from surgically resected HCC cases during 1994-2017 in our department. Results: Preoperative serum AFP values of HCC-BC cases (n=284) were higher compared to HCC-NBNC cases (n=88) (p=0.016), whereas serum DCP values of HCC-NBNC cases were higher compared to HCC-BC cases (p<0.001). Multivariable analyses indicated that abnormal serum AFP [hazard ratio (HR)=1.46, 95% conficdence interval (CI)=1.03-2.07, p=0.035) was one of the significant recurrence-free survival predictors of HCC-BC cases, while abnormal serum DCP (HR=4.99, 95%CI=1.91-13.01, p=0.001) was one of the significant recurrence-free survival predictors of HCC-NBNC cases. Conclusion: HCC-NBNC cases have a different tumor marker profile from HCC-BC cases. Elevated DCP could be both a diagnostic and prognostic marker of HCC-NBNC patients.

    DOI: 10.21873/invivo.12434

    Web of Science

    Scopus

    PubMed

  9. Phase Ib/IIStudy of BiweeklyTAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTSStudy)

    Satake Hironaga, Kato Takeshi, Oba Koji, Kotaka Masahito, Kagawa Yoshinori, Yasui Hisateru, Nakamura Masato, Watanabe Takanori, Matsumoto Toshihiko, Kii Takayuki, Terazawa Tetsuji, Makiyama Akitaka, Takano Nao, Yokota Mitsuru, Okita Yoshihiro, Matoba Koreatsu, Hasegawa Hiroko, Tsuji Akihito, Komatsu Yoshito, Yoshino Takayuki, Yamazaki Kentaro, Mishima Hideyuki, Oki Eiji, Nagata Naoki, Sakamoto Junichi

    ONCOLOGIST   25 巻 ( 12 ) 頁: E1855 - E1863   2020年12月

     詳細を見る

    記述言語:英語   出版者・発行元:Oncologist  

    Lessons Learned: A biweekly TAS-102 plus BEV schedule in patients with heavily pretreated mCRC showed equivalent efficacy with less toxicity compared with the current schedule of TAS-102 plus BEV combination. Biweekly TAS-102 plus BEV combination could reduce unnecessary dose reduction of TAS-102, maintain higher doses, and possibly be effective even in cases without chemotherapy-induced neutropenia (CIN). The prespecified subgroup analysis of this study showed an obvious association between CIN within the first two cycles and prognosis of biweekly TAS-102 plus BEV. Background: TAS-102 (trifluridine/tipiracil) plus bevacizumab (BEV) combination therapy has shown promising activity in patients with metastatic colorectal cancer (mCRC). However, the previously reported dose and schedule for the TAS-102 (70 mg/m2/day on days 1–5 and 8–12, every 4 weeks) plus BEV (5 mg/kg on day 1, every 2 weeks) regimen is complicated by severe hematological toxicities and difficult administration schedules. Here, we evaluated the efficacy and safety of a more convenient biweekly TAS-102 plus BEV combination. Methods: Patients with mCRC who were refractory or intolerant to standard chemotherapies were enrolled. Patients received biweekly TAS-102 (twice daily on days 1–5, every 2 weeks) with BEV (5mg/kg on day 1, every 2 weeks). The primary endpoint was progression-free survival rate at 16 weeks (16-w PFS rate). Results: From October 2017 to January 2018, 46 patients were enrolled. The recommended phase II dose was determined to be TAS-102 (70 mg/m2/day). Of the 44 eligible patients, the 16-w PFS rate was 40.9% (95% confidence interval, 26.3%–56.8%), and the null hypothesis was rejected (p <.0001). Median progression-free survival (PFS) and overall survival were 4.29 months and 10.86 months, respectively. Disease control rate was 59.1%. Common grade 3 or higher adverse events were hypertension (40.9%), neutropenia (15.9%), and leucopenia (15.9%). Conclusion: Biweekly TAS-102 plus BEV showed promising antitumor activity with safety.

    DOI: 10.1634/theoncologist.2020-0643

    Web of Science

    Scopus

    PubMed

  10. Final results of multicenter phase Ib/ II study of biweekly trifluridine/tipiracil with bevacizumab combination for patients with mCRC refractory to standard therapies (BiTS study)

    Nakamura Masato, Satake Hironaga, Oba Koji, Kotaka Masahito, Kagawa Yoshinori, Yasui Hisateru, Watanabe Takanori, Matsumoto Toshihiko, Kii Takayuki, Terazawa Tetsuji, Makiyama Akitaka, Takano Nao, Yokota Mitsuru, Okita Yoshihiro, Matoba Koreatsu, Hasegawa Hiroko, Tsuji Akihito, Nagata Naoki, Sakamoto Junichi, Kato Takeshi

    JOURNAL OF CLINICAL ONCOLOGY   38 巻 ( 4 )   2020年2月

     詳細を見る

  11. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study

    Takano Nao, Yamada Suguru, Hirakawa Akihiro, Yokoyama Yukihiro, Kawashima Hiroki, Maeda Osamu, Okada Tohru, Ohno Eizaburo, Yamaguchi Junpei, Ishikawa Takuya, Sonohara Fuminori, Suenaga Masaya, Takami Hideki, Hayashi Masamichi, Niwa Yukiko, Hirooka Yoshiki, Ito Yoshiyuki, Naganawa Shinji, Ando Yuichi, Nagino Masato, Goto Hidemi, Fuji Tsutomu, Kodera Yasuhiro

    NAGOYA JOURNAL OF MEDICAL SCIENCE   81 巻 ( 2 ) 頁: 233 - 239   2019年5月

     詳細を見る

    記述言語:英語   出版者・発行元:Nagoya journal of medical science  

    The efficacy of nab-paclitaxel combined with gemcitabine (GnP) and of chemoradiotherapy (CRT) for unresectable locally advanced pancreatic ductal adenocarcinoma (UR-LA PDAC) is still unclear. We previously conducted a phase I study of CRT using GnP and determined the recommended dose and have now designed a phase II trial to evaluate the efficacy of CRT incorporating GnP for UR-LA PDAC. Eligibility criteria are chemotherapy-naïve patients with UR-LA PDAC as defined by the NCCN guidelines version 2. 2016. Study patients will receive 100 mg/m2 nab-paclitaxel and 800 mg/m2 gemcitabine on Days 1, 8, and 15 per 4-week cycle with concurrent radiation therapy (total dose of 50.4 Gy in 28 fractions of 1.8 Gy per day, 5 days per week). Treatment will be continued until disease progression or surgery, which is to be performed only for patients in whom the disease is well-controlled at 8 months from beginning the protocol treatment. Primary endpoint is 2-year overall survival rate and co-primary endpoint is resection rate. Secondary endpoints are overall survival, progression free survival, time to treatment failure, response rate, disease control rate, early tumor shrinkage, depth of response, reduction of SUV-max on PET-CT, serum tumor markers, relative dose intensity, safety, and Quality of life. This study will show the efficacy and safety of chemoradiotherapy combined with GnP.

    DOI: 10.18999/nagjms.81.2.233

    Web of Science

    Scopus

    PubMed

  12. Multicenter phase Ib/II study of biweekly trifluridine/tipiracil with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BITS study).

    Kotaka Masahito, Satake Hironaga, Oba Koji, Kagawa Yoshinori, Yasui Hisateru, Nakamura Masato, Watanabe Takanori, Matsumoto Toshihiko, Kii Takayuki, Terazawa Tetsuji, Makiyama Akitaka, Takano Nao, Yokota Mitsuru, Okita Yoshihiro, Matoba Koreatsu, Hasegawa Hiroko, Tsuji Akihito, Nagata Naoki, Sakamoto Junichi, Kato Takeshi

    JOURNAL OF CLINICAL ONCOLOGY   37 巻 ( 4 )   2019年2月

  13. A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial

    Munemoto Yoshinori, Kanda Mitsuro, Oba Koji, Kim Ho Min, Takemoto Hiroyoshi, Denda Tadamichi, Nagata Naoki, Takano Nao, Fukunaga Mutsumi, Kataoka Masato, Tokunaga Yukihiko, Sakamoto Junichi, Mishima Hideyuki

    CANCER CHEMOTHERAPY AND PHARMACOLOGY   81 巻 ( 5 ) 頁: 829 - 838   2018年5月

     詳細を見る

    記述言語:英語   出版者・発行元:Cancer Chemotherapy and Pharmacology  

    Purpose: Fluorouracil monotherapy, instead of the FOLFOX or FOLFIRI regimen, is administered to patients intolerant to oxaliplatin or irinotecan because of their adverse effects. A prospective clinical trial was designed to evaluate the efficacy and safety of fluorouracil monotherapy combined with panitumumab administered to patients with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) intolerant to oxaliplatin and irinotecan. Screening for potential serum biomarkers to predict early therapeutic responses was conducted. Methods: This single-arm, open-label multicenter phase II trial recruited patients with KRAS WT mCRC from 16 institutes between January 2012 and October 2014. Panitumumab (6 mg/kg) was intravenously administered every 2 weeks, combined with fluorouracil monotherapy, in 2-week cycles. The primary objective was overall response rate, and secondary endpoints included disease-control rate, progression-free survival, overall survival, toxicity, and blood-test data. Results: Forty patients (male, 65.0%; median age, 74 years; colon cancer, 72.5%) met eligibility criteria and received 7 cycles (median) of fluorouracil chemotherapy combined with panitumumab. There were no treatment-related deaths. Median time to treatment failure was 3.2 months. 23 (57.5%) patients experienced at least one adverse effect ≥ grade 3. The response rate was 10.0% (95% confidence interval 2.8–23.7%). Median progression-free survival and overall survival were 4.3 and 11.3 months, respectively. Total lactase dehydrogenase (LDH) levels and those of LDH-4 and LDH-5, quickly changed with disease reduction or progression. Conclusions: Fluorouracil monotherapy combined with panitumumab was safely administered to patients with KRAS WT mCRC intolerant to oxaliplatin and irinotecan. Serum LDH levels may predict early responses.

    DOI: 10.1007/s00280-018-3556-1

    Web of Science

    Scopus

    PubMed

  14. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer

    Yamada Suguru, Fujii Tsutomu, Yokoyama Yukihiro, Kawashima Hiroki, Maeda Osamu, Suzuki Kojiro, Okada Tohru, Ono Eizaburo, Yamaguchi Junpei, Takano Nao, Takami Hideki, Hayashi Masamichi, Niwa Yukiko, Hirooka Yoshiki, Ito Yoshiyuki, Naganawa Shinji, Ando Yuichi, Nagino Masato, Goto Hidemi, Kodera Yasuhiro

    CANCER CHEMOTHERAPY AND PHARMACOLOGY   81 巻 ( 5 ) 頁: 815 - 821   2018年5月

     詳細を見る

    記述言語:英語   出版者・発行元:Cancer Chemotherapy and Pharmacology  

    Purpose: For unresectable locally advanced (UR-LA) pancreatic cancer, chemoradiotherapy has been recommended by the NCCN guidelines. We designed a chemoradiotherapy protocol using nab-paclitaxel combined with gemcitabine (GnP) for patients with UR-LA pancreatic cancer. The purpose of this phase I study was to determine a recommended dose (RD) for this novel regimen. Methods: Patients with UR-LA pancreatic cancer were eligible. The frequency of dose-limiting toxicities (DLTs) was evaluated, and the RD was determined. Patients were classified according to the designated dose levels of chemoradiotherapy using the GnP regimen. After additional 6 cycles of the GnP regimen were administered, surgery was considered if the patients had stable disease and tumor marker levels had normalized. Results: DLT (grade 4 thrombocytopenia) was observed only in 1 of 12 patients, and the RD was set at level 3. Grade 3–4 leukopenia was observed in 9 (75.0%) patients, and neutropenia in 7 (58.3%). The response rate was 41.7%, and the disease control rate was 100%. Conversion surgery was performed in 6 (50%) patients, and curative resection (R0) was performed in all 6 patients (100%). Stratification according to the Evans classification system demonstrated one patient with grade 1b, one with grade 2, two with grade 3, and two with grade 4 disease. Conclusion: The RD for weekly administration was 800 mg/m2 for gemcitabine and 100 mg/m2 for nab-paclitaxel with a 50.4 Gy radiation. The GnP regimen at this dosage was promising with 6 of 12 patients proceeding to conversion surgery, and should be evaluated further in a phase II trial.

    DOI: 10.1007/s00280-018-3554-3

    Web of Science

    Scopus

    PubMed

  15. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer.

    Yamada Suguru, Fujii Tsutomu, Takano Nao, Takami Hideki, Suenaga Masaya, Niwa Yukiko, Hayashi Masamichi, Iwata Naoki, Kanda Mitsuro, Kobayashi Daisuke, Tanaka Chie, Nakayama Goro, Sugimoto Hiroyuki, Koike Masahiko, Fujiwara Michitaka, Kodera Yasuhiro

    JOURNAL OF CLINICAL ONCOLOGY   36 巻 ( 4 )   2018年2月

  16. 1.膵癌取扱い規約第7版における変更の要点と新たな切除可能性分類

    山田 豪, 高野 奈緒, 小寺 泰弘

    膵臓   33 巻 ( 1 ) 頁: 12 - 17   2018年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本膵臓学会  

    <p>米国のNCCNガイドラインにより膵癌における切除可能性分類が提唱され,日常診療において広く浸透しているが,年々修正が重ねられ,やや煩雑であることが指摘されてきた.昨年,膵癌取扱い規約(JPS)第7版が刊行され,UICC第7版との整合性を図るために,T分類,N分類,病期分類などが変更された.さらに,新たに組織学的効果判定基準が記載され,本邦独自の切除可能性分類も提唱された.本切除可能性分類に基づき,当教室における術前治療未施行の膵癌切除症例の生存成績を解析した結果,特に門脈系血管への接触・浸潤の程度に基づくJPS第7版によるBR膵癌の定義は妥当であると考えられた.本切除可能性分類はNCCNガイドラインと比較して,より簡便かつ明確な記載がなされており,治療方針の決定に寄与するだけでなく,臨床試験を遂行する際には非常に有用であると考えられる.</p>

    DOI: 10.2958/suizo.33.12

    CiNii Research

  17. The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)

    Nakayama Goro, Ishigure Kiyoshi, Yokoyama Hiroyuki, Uehara Keisuke, Kojima Hiroshi, Ishiyama Akiharu, Hayashi Naomi, Takano Nao, Hattori Norifumi, Kobayashi Daisuke, Tanaka Chie, Hayashi Masamichi, Kanda Mitsuro, Yamada Suguru, Sugimoto Hiroyuki, Koike Masahiko, Fujiwara Michitaka, Fujii Tsutomu, Murotani Kenta, Ando Yuichi, Kodera Yasuhiro

    BMC CANCER   17 巻 ( 1 ) 頁: 243   2017年4月

     詳細を見る

    記述言語:英語   出版者・発行元:BMC Cancer  

    Background: The aim of this study was to evaluate the efficacy and safety of CapeOX plus bevacizumab with a planned oxaliplatin stop-and-go strategy in Japanese patients with metastatic colorectal cancer (mCRC). Methods: Patients with untreated mCRC were treated with 4 cycles of CapeOX plus bevacizumab therapy, followed by capecitabine plus bevacizumab maintenance therapy. Reintroduction of oxaliplatin was scheduled after 8 cycles of maintenance therapy or upon tumor progression. The primary endpoint was progression-free survival (PFS), and secondary end points included overall survival (OS), objective response rate to each treatment, reintroduction rate of oxaliplatin, frequency of peripheral sensory neuropathy (PSN), and safety. Results: The 52 patients who received the protocol treatment were included in the evaluation of efficacy and safety. Median PFS and OS were 12.4 months (95% confidence interval [CI], 10.0-14.8) and 30.6 months (95% CI, 27.6-33.5), respectively. The objective response rates were 55.8% for the initial CapeOX plus bevacizumab therapy, 17.8% for capecitabine plus bevacizumab maintenance therapy, and 31.0% for reintroduced CapeOX plus bevacizumab therapy. The frequency of PSN was 63.5%, including 3.8% of patients with grade 3 PSN. No patients required treatment discontinuation because of PSN during the induction or maintenance therapy. Conclusions: CapeOX plus bevacizumab therapy with a planned oxaliplatin stop-and-go strategy is a feasible first-line treatment for Japanese patients with mCRC. Trial registration: This trial is registered with the University Hospital Medical Information Network in 15 March 2010 ( UMIN000006478 ).

    DOI: 10.1186/s12885-017-3245-1

    Web of Science

    Scopus

    PubMed

  18. Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma.

    Ninomiya Go, Fujii Tsutomu, Yamada Suguru, Asano Tomonari, Takano Nao, Takami Hideki, Iwata Naoki, Kanda Mitsuro, Niwa Yukiko, Hayashi Masamichi, Kobayashi Daisuke, Tanaka Chie, Nakayama Goro, Sugimoto Hiroyuki, Fujiwara Michitaka, Koike Masahiko, Kodera Yasuhiro

    JOURNAL OF CLINICAL ONCOLOGY   35 巻 ( 4 )   2017年2月

  19. Clinical implication of inflammation-based prognostic score and perioperative nutrition control in pancreatic cancer.

    Takano Nao, Yamada Suguru, Fujii Tsutomu, Tashiro Mitsuru, Tanaka Nobutake, Morimoto Daishi, Ninomiya Go, Niwa Yukiko, Takami Hideki, Iwata Naoki, Hayashi Masamichi, Kanda Mitsuro, Tanaka Chie, Kobayashi Daisuke, Nakayama Goro, Sugimoto Hiroyuki, Koike Masahiko, Fujiwara Michitaka, Kodera Yasuhiro

    JOURNAL OF CLINICAL ONCOLOGY   35 巻 ( 4 )   2017年2月

  20. The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer

    Kataoka Masato, Kanda Mitsuro, Ishigure Kiyoshi, Matsuoka Hiroshi, Sato Yusuke, Takahashi Takao, Tanaka Chihiro, Deguchi Tomohiro, Shibata Yoshihisa, Sato Mikinori, Inagaki Hitoshi, Matsui Takanori, Kondo Akinori, Takano Nao, Tanaka Haruyoshi, Sakamoto Junichi, Oba Koji, Kondo Ken

    ANNALS OF SURGICAL ONCOLOGY   24 巻 ( 2 ) 頁: 546 - 553   2017年2月

     詳細を見る

    記述言語:英語   出版者・発行元:Annals of Surgical Oncology  

    Background: Advantages of neoadjuvant chemotherapy combined with monoclonal antibodies for treating patients with resectable colorectal cancer liver metastasis (CLM) have not been established. The purpose of this study was to evaluate the efficacy and safety of oxaliplatin-based regimen (FOLFOX or XELOX) plus monoclonal antibodies (cetuximab or bevacizumab) treatment in patients with resectable CLM. Methods: A single-arm, open-label, multicenter, phase II trial was conducted for patients aged ≥ 20 years with resectable and untreated CLM. Patients received preoperative FOLFOX (6 cycles) or XELOX (4 cycles). Cetuximab or bevacizumab was administered to patients with wild-type or mutated KRAS codons 12 and 13, respectively. The primary endpoint was progression-free survival (PFS). Results: Between January 2010 and June 2012, 47 patients were enrolled from 12 institutions. Wild-type or mutant KRAS sequences were examined in 32 and 15 patients, respectively. Twenty-one (45 %) patients experienced Grades 3/4 adverse events, and 55 % of all patients responded to therapy. The sizes of tumors of patients in the wild-type KRAS group were significantly reduced compared with those of the mutant KRAS group. The overall rates of liver resection and postoperative morbidity were 83 and 14 %, respectively, and the median PFS was 15.6 months. The median PFS times of the KRAS wild-type and mutant groups were 22.5 months and 10.5 months, respectively. Conclusions: Neoadjuvant therapy using FOLFOX/XELOX combined with monoclonal antibodies did not improve PFS, although it was administered safely and had less adverse effects after liver resection.

    DOI: 10.1245/s10434-016-5557-9

    Web of Science

    Scopus

    PubMed

  21. <i>PAX5</i> gene as a novel methylation marker that predicts both clinical outcome and cisplatin sensitivity in esophageal squamous cell carcinoma

    Kurimoto Keisuke, Hayashi Masamichi, Guerrero-Preston Rafael, Koike Masahiko, Kanda Mitsuro, Hirabayashi Sho, Tanabe Hiroshi, Takano Nao, Iwata Naoki, Niwa Yukiko, Takami Hideki, Kobayashi Daisuke, Tanaka Chie, Yamada Suguru, Nakayama Goro, Sugimoto Hiroyuki, Fujii Tsutomu, Fujiwara Michitaka, Kodera Yasuhiro

    EPIGENETICS   12 巻 ( 10 ) 頁: 865 - 874   2017年

     詳細を見る

    記述言語:英語   出版者・発行元:Epigenetics  

    Therapeutic strategies for esophageal cancer largely depend on histopathological assessment. To select appropriate treatments of individual patients, we examined the background molecular characteristics of tumor malignancy and sensitivity to multidisciplinary therapy. Seventy-eight surgically-resected esophageal squamous cell carcinoma (ESCC) cases during 2001–2013 were examined. PAX5, a novel gene methylation marker in ESCC, was evaluated in the specimens, as methylation of this gene was identified as an extremely tumor-specific event in squamous cell carcinogenesis of head and neck. PAX5 methylation status was evaluated by quantitative MSP (QMSP) assays. Mean QMSP value was 15.7 (0–136.3) in ESCCs and 0.3 (0–8.6) in adjacent normal tissues (P < 0.001). The 78 cases were divided into high QMSP value (high QMSP, n = 26) and low QMSP value (low QMSP, n = 52). High QMSP cases were significantly associated with downregulated PAX5 expression (P = 0.040), and showed significantly poor recurrence-free survival [Hazard Ratio (HR) = 2.84; P = 0.005; 95% Confidence Interval (CI): 1.39–5.81] and overall survival (HR = 3.23; P = 0.002; 95%CI: 1.52–7.01) in multivariable analyses with histopathological factors. PAX5-knockdown cells exhibited significantly increased cell proliferation and cisplatin resistance. PAX5 gene methylation can predict poor survival outcomes and cisplatin sensitivity in ESCCs and could be a useful diagnostic tool for cancer therapy selection.

    DOI: 10.1080/15592294.2017.1365207

    Web of Science

    Scopus

    PubMed

  22. A resected case of symptomatic acinar cell cystadenoma of the pancreas displacing the main pancreatic duct.

    Tanaka H, Hatsuno T, Kinoshita M, Hasegawa K, Ishihara H, Takano N, Shimoyama S, Nakayama H, Kataoka M, Ichihara S, Kanda M, Kodera Y, Kondo K

    Surgical case reports   2 巻 ( 1 ) 頁: 39   2016年12月

     詳細を見る

    記述言語:英語  

    DOI: 10.1186/s40792-016-0166-1

    PubMed

  23. The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer (vol 24, pg 546, 2017)

    Kataoka Masato, Kanda Mitsuro, Ishigure Kiyoshi, Matsuoka Hiroshi, Sato Yusuke, Takahashi Takao, Tanaka Chihiro, Deguchi Tomohiro, Shibata Yoshihisa, Sato Mikinori, Inagaki Hitoshi, Matsui Takanori, Kondo Akinobu, Takano Nao, Tanaka Haruyoshi, Sakamoto Junichi, Oba Koji, Kondo Ken

    ANNALS OF SURGICAL ONCOLOGY   23 巻 ( Suppl 5 ) 頁: S1064 - S1064   2016年12月

     詳細を見る

    記述言語:英語   出版者・発行元:Annals of Surgical Oncology  

    Akinobu Kondo’s first name is incorrect in the original article. It is corrected as shown in this erratum. Also, the following Acknowledgment was inadvertently omitted: Acknowledgment This study was supported, in part, by the nonprofit organization Epidemiological and Clinical Research Information Network (ECRIN).

    DOI: 10.1245/s10434-016-5593-5

    Web of Science

    Scopus

    PubMed

  24. Protein tyrosine kinase 7: a hepatocellular carcinoma-related gene detected by triple-combination array

    Hishida Mitsuhiro, Inokawa Yoshikuni, Takano Nao, Nishikawa Yoko, Iwata Naoki, Kanda Mitsuro, Tanaka Chie, Kobayashi Daisuke, Yamada Suguru, Nakayama Goro, Fujii Tsutomu, Sugimoto Hiroyuki, Koike Masahiko, Fujiwara Michitaka, Kodera Yasuhiro, Nomoto Shuji

    JOURNAL OF SURGICAL RESEARCH   195 巻 ( 2 ) 頁: 444 - 453   2015年5月

     詳細を見る

    記述言語:英語   出版者・発行元:Journal of Surgical Research  

    Background Hepatocellular carcinoma (HCC) is one of the top five causes of cancer-related deaths worldwide. We developed a novel technique to identify cancer-related genes of HCC as follows: triple-combination array analysis, which combines gene expression profiles, single nucleotide polymorphism arrays, and methylation arrays. Materials and methods Triple-combination array analysis was performed on one HCC sample from a 68-y-old female patient, and one candidate cancer-related gene was selected. Subsequently, we analyzed the identified gene by quantitative real-time reverse-transcriptase polymerase chain reaction (PCR) and methylation-specific PCR in nine HCC cell lines and in samples from 48 HCC patients. Additionally, we evaluated gene expression by immunohistochemistry and Western blotting. Results Using this method, protein tyrosine kinase 7 (PTK7) was detected as a candidate cancer-related gene. PTK7 was revealed to be hypermethylated (methylation value 0.826, range 0-1.0) in cancer tissue, compared with that of adjacent noncancerous tissues (0.047) by methylation array. Of the 48 clinical samples, 30 HCC samples (62.5%) showed PTK7 promoter hypermethylation. Downregulation of PTK7 (expressions in tumor tissues decreased by ≥50% compared with the noncancerous tissues) was significantly associated with age >60 y (P = 0.030) and elevation in serum protein induced by vitamin K absence or antagonists-II (P = 0.033). Moreover, patients with downregulation were significantly inferior in overall survival (P < 0.001) than the others. Conclusions Our data imply that PTK7 acts as a cancer-related gene and may be a potent prognostic marker for HCC. Triple-combination array analysis was once again found to be useful in identifying cancer-related genes.

    DOI: 10.1016/j.jss.2014.12.045

    Web of Science

    Scopus

    PubMed

  25. <i>CCNJ</i> detected by triple combination array analysis as a tumor-related gene of hepatocellular carcinoma

    Takano Nao, Hishida Mitsuhiro, Inokawa Yoshikuni, Hayashi Masamichi, Kanda Mitsuro, Nishikawa Yoko, Iwata Naoki, Kobayashi Daisuke, Tanaka Chie, Yamada Suguru, Nakayama Goro, Fujii Tsutomu, Sugimoto Hiroyuki, Koike Masahiko, Fujiwara Michitaka, Kodera Yasuhiro, Nomoto Shuji

    INTERNATIONAL JOURNAL OF ONCOLOGY   46 巻 ( 5 ) 頁: 1963 - 1970   2015年5月

     詳細を見る

    記述言語:英語   出版者・発行元:International Journal of Oncology  

    Hepatocellular carcinoma (HCC) has a high likelihood of recurrence and a poor prognosis. To detect cancer-related genes of HCC, we developed a new technique: triple combination array analysis, consisting of a methylation array, a gene expression array and a single nucleotide polymorphism array. A surgical specimen obtained from a 68-year-old female HCC patient was analyzed using triple combination array, which identified cyclin J (CCNJ) as a candidate cancer-related gene of HCC. Subsequently, samples from 85 HCC patients were evaluated for CCNJ promoter hypermethylation and expression status using methylation-specific PCR (MSP) and quantitative reverse transcriptase RT-PCR, respectively. CCNJ was found to be hypermethylated (methylation value, 0.906; range, 0-1.0) in cancer tissue, compared with adjacent non-cancerous tissue (0.112) using a methylation array. MSP revealed that CCNJ was hypermethylated in 67 (78.8%) of the tumor samples. CCNJ expression was significantly decreased in cases with hypermethylation (P<0.0001). Furthermore, cases with both promoter hypermethylation and decreased expression of CCNJ in the tumor tissue had a worse overall survival than the other cases (P=0.0383). In conclusion, our results indicated that CCNJ could be a novel prognostic marker of HCC, and this study indicated that triple combination array analysis was effective in detecting new tumor-related genes and their mechanisms.

    DOI: 10.3892/ijo.2015.2892

    Web of Science

    Scopus

    PubMed

  26. High expression of Janus kinase 2 in background normal liver tissue of resected hepatocellular carcinoma is associated with worse prognosis

    Sonohara Fuminori, Nomoto Shuji, Inokawa Yoshikuni, Hishida Mitsuhiro, Takano Nao, Kanda Mitsuro, Nishikawa Yoko, Fujii Tsutomu, Koike Masahiko, Sugimoto Hiroyuki, Kodera Yasuhiro

    ONCOLOGY REPORTS   33 巻 ( 2 ) 頁: 767 - 773   2015年2月

     詳細を見る

    記述言語:英語   出版者・発行元:Oncology Reports  

    When assessing hepatocellular carcinoma (HCC), it is important to examine prognostic factors in the background normal liver tissue and consider malignant aspects of the primary lesion. Candidate genes were extracted from the background normal liver samples via multiarray analysis. Control samples, termed supernormal (SN) liver, were obtained from 11 cases of metastatic liver cancer. Corresponding normal (CN) liver tissue was surgically obtained from a typical HCC patient with chronic hepatitis C background for comparison. Expression profile and methylation array demonstrated that Janus kinase 2 (JAK2) gene expression was increased by 2.378-fold in the CN tissue. Methylation array reported a lower value for CN (0.125) than SN tissues (0.748). We then investigated JAK2 expression by real-time quantitative reverse transcription-polymerase chain reaction in 100 consecutive resected HCC cases. The average expression level of JAK2 (normalized to GAPDH) was significantly lower in CN (9.24±6.43, n=100) than in SN (35.21±21.38, n=11) tissues (P<0.001). As such a result was contrary to our expectation, the case used for array analysis seemed to be a rare incidence. One hundred HCC cases were subsequently divided into two groups based on JAK2 expression in the adjacent normal tissue: one consisting of the upper 70% of cases (n=70) and the other of the remaining 30% (n=30). Higher JAK2 expression in the adjacent tissue demonstrated significant correlation with worse survival (P=0.022). Furthermore, multivariate analysis identified higher JAK2 expression in the background normal liver tissue of HCC as an independent prognostic factor (P=0.032). Our findings suggest that higher JAK2 expression in the background normal liver tissue of HCC may be a good prognostic biomarker for resected HCC.

    DOI: 10.3892/or.2014.3621

    Web of Science

    Scopus

    PubMed

  27. Evaluation of two-dimensional response to predict overall survival in patients with metastatic colorectal cancer treated with the first-line bevacizumab-based chemotherapy

    Nakayama Goro, Takano Nao, Tanaka Chie, Kobayashi Daisuke, Koike Masahiko, Fujiwara Michitaka, Kodera Yasuhiro

    JOURNAL OF CLINICAL ONCOLOGY   33 巻 ( 3 )   2015年1月

  28. The study of efficacy and safety of chemotherapy plus bevacizumab with oxaliplatin stop-and-go strategy in first-line treatment for metastatic colorectal cancer.

    Takano Nao, Nakayama Goro, Kodera Yasuhiro

    JOURNAL OF CLINICAL ONCOLOGY   33 巻 ( 3 )   2015年1月

  29. 左卵巣静脈原発平滑筋肉腫の1例

    高野 奈緒, 片岡 政人, 稲岡 健一, 中山 裕史, 竹田 伸, 近藤 建

    日本臨床外科学会雑誌   76 巻 ( 2 ) 頁: 396 - 400   2015年

     詳細を見る

    記述言語:日本語   出版者・発行元:日本臨床外科学会  

    症例は65歳,女性.左下腹部の腫瘤を主訴に近医を受診,CTにて左下腹部に腫瘍を認め,当院紹介となった.精査にて左卵巣癌または平滑筋肉腫の診断にて開腹手術を施行した.開腹所見上腫瘍は左卵巣静脈へ進展するように存在したが,左正常卵巣は存在し,腫瘍摘除および左付属器摘除術を施行した.病理組織学的に左卵巣静脈壁平滑筋組織は腫瘍と連続しており,免疫組織染色にてdesmin・muscle specific actin陽性,S-100・CD34・c-kit陰性にて,左卵巣静脈原発平滑筋肉腫と診断した.経過良好で,術後6カ月経過し再発は認めていない.卵巣静脈原発の平滑筋肉腫は稀な疾患であり,切除した1例を経験したので報告する.

    DOI: 10.3919/jjsa.76.396

    CiNii Research

  30. Correlation between worse prognosis and higher expression of the <i>JAK2</i> gene in corresponding non-neoplastic tissue in patients with hepatocellular carcinoma, extracted by multiarray analysis

    Nomoto Shuji, Hishida Mitsuhiro, Inokawa Yoshikuni, Takano Nao, Kanda Mitsuro, Kodera Yasuhiro

    CANCER RESEARCH   74 巻 ( 19 )   2014年10月

  31. ZGPAT gene expression in non-tumor hepatocellular carcinoma tissue is a likely biomarker for survival risk

    Hishida Mitsuhiro, Nomoto Shuji, Inokawa Yoshikuni, Takano Nao, Kanda Mitsuro, Iwata Naoki, Tanaka Chie, Kobayashi Daisuke, Nishikawa Yoko, Yamada Suguru, Nakayama Goro, Fujii Tsutomu, Sugimoto Hiroyuki, Koike Masahiko, Fujiwara Michitaka, Kodera Yasuhiro

    CANCER RESEARCH   74 巻 ( 19 )   2014年10月

  32. Detection of the Cyclin J (CCNJ) as a new cancer-related gene in human hepatocellular carcinoma by using a method of triple combination array analysis

    Takano Nao, Nomoto Shuji, Hishida Mitsuhiro, Inokawa Yoshikuni, Hayashi Masamichi, Kanda Mitsuro, Okamura Yukiyasu, Nishikawa Yoko, Tanaka Chie, Kobayashi Daisuke, Yamada Suguru, Nakayama Goro, Fujii Tsutomu, Sugimoto Hiroyuki, Koike Masahiko, Fujii Michitaka, Takeda Shin, Kodera Yasuhiro

    CANCER RESEARCH   74 巻 ( 19 )   2014年10月

  33. Correlation between worse prognosis and lower expression of the <i>TPPP</i> gene in patients with hepatocellular carcinoma, detected by multiarray analysis

    Inokawa Yoshikuni, Nomoto Shuji, Hishida Mitsuhiro, Takano Nao, Kanda Mitsuro, Fujiwara Michitaka, Koike Masahiko, Sugimoto Hiroyuki, Fujii Tsutomu, Nakayama Goro, Yamada Suguru, Tanaka Chie, Kobayashi Daisuke, Iwata Naoki, Kodera Yasuhiro

    CANCER RESEARCH   74 巻 ( 19 )   2014年10月

  34. Expression Analysis of <i>THOP1</i> in Background Liver, a Prognostic Predictive Factor in Hepatocellular Carcinoma, Extracted by Multiarray Analysis

    Nomoto Shuji, Hishida Mitsuhiro, Inokawa Yoshikuni, Takano Nao, Kanda Mitsuro, Nishikawa Yoko, Fujii Tsutomu, Koike Masahiko, Sugimoto Hiroyuki, Kodera Yasuhiro

    ANNALS OF SURGICAL ONCOLOGY   21 巻 ( SUPPL. 3 ) 頁: 443 - 450   2014年6月

     詳細を見る

    記述言語:英語   出版者・発行元:Annals of Surgical Oncology  

    Background. Hepatocellular carcinoma (HCC) often recurs and multicentric occurrence is more common than intrahepatic metastases after surgery. Prognostic prediction is insufficient when considering only factors in resected primary tumor. Methods. Control samples, termed supernormal (SN) liver, were taken from 11 cases of metastatic secondary malignancies of the liver. We selected adjacent nonneoplastic liver tissue from a patient with HCC and liver cirrhosis by hepatitis C (CN) for comparison. Results. Expression profiling and methylation arrays were performed. We identified genes showing differences in both arrays. Prognosis was predicted for 179 cases of HCC based on gene expression. Expression profiling showed that expression of thimet oligopeptidase (THOP1) gene was decreased 4.119-fold in CN. Methylation array showed a higher value for CN (0.869) than SN (0.488). We studied THOP1 gene expression by real-time reverse transcriptase polymerase chain reaction. The average expression level of THOP1 (THOP1 value × 103/GAPDH) decreased in matching normal tissue (14.53 ± 10.14) relative to SN (78.14 ± 44.50). The group with higher than average THOP1 expression (n = 74) showed significant correlations with prolonged survival (P = 0.0383). Strongly reduced THOP1 expression (<3.0, n = 50) was shown to be an independent prognostic factor by multivariate analysis (P = 0.0024). Conclusions. Expression of the THOP1 gene in the background liver of HCC is likely to be a good biomarker for risk of HCC development. When assessing HCC, it is important to extract prognostic factors from background liver tissue as well as considering malignant factors of the primary cancer lesion. © 2014 Society of Surgical Oncology.

    DOI: 10.1245/s10434-014-3581-1

    Web of Science

    Scopus

    PubMed

  35. OP-043-6 進行再発大腸癌に対するベバシズマブ併用一次治療に対する定量的抗腫瘍評価と予後の関連に関する検討(OP-043 大腸 化学療法-1,一般演題,第114回日本外科学会定期学術集会)

    中山 吾郎, 村井 俊文, 高見 秀樹, 藪崎 太郎, 高野 奈緒, 田中 千恵, 小林 大介, 藤井 努, 杉本 博行, 小池 聖彦, 小寺 泰弘

    日本外科学会雑誌   115 巻 ( 2 ) 頁: 392   2014年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人日本外科学会  

    CiNii Research

  36. WS-10-3 大腸癌手術の周術期における体組成変化についての検討(WS-10 ワークショップ(10)外科診療におけるNSTの役割と将来像,第114回日本外科学会定期学術集会)

    薮崎 紀充, 中山 吾郎, 高野 奈緒, 高見 秀樹, 村井 俊文, 藤井 努, 杉本 博行, 野本 周嗣, 小池 聖彦, 藤原 道隆, 小寺 泰弘

    日本外科学会雑誌   115 巻 ( 2 ) 頁: 227   2014年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人日本外科学会  

    CiNii Research

  37. PS-157-5 正常肝とHCC背景肝の比較から抽出したJAK2遺伝子の発現の検討(PS-157 肝 肝細胞癌-4,ポスターセッション,第114回日本外科学会定期学術集会)

    野本 周嗣, 菱田 光洋, 猪川 祥邦, 高野 奈緒, 杉本 博行, 藤井 努, 神田 光郎, 小池 聖彦, 藤原 道隆, 小寺 泰弘

    日本外科学会雑誌   115 巻 ( 2 ) 頁: 889   2014年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人日本外科学会  

    CiNii Research

  38. PS-084-1 背景肝の比較から抽出したZGPAT遺伝子の発現の検討(PS-084 肝 基礎-4,ポスターセッション,第114回日本外科学会定期学術集会)

    菱田 光洋, 野本 周嗣, 高野 奈緒, 猪川 祥邦, 岩田 直樹, 神田 光郎, 田中 千恵, 小林 大介, 山田 豪, 中山 吾郎, 藤井 努, 杉本 博行, 小池 聖彦, 藤原 道隆, 小寺 泰弘

    日本外科学会雑誌   115 巻 ( 2 ) 頁: 742   2014年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人日本外科学会  

    CiNii Research

  39. PS-038-2 大腸癌術後補助化学療法におけるオキサリプラチンの末梢神経障害に関する検討(PS-038 大腸 化学療法-2,ポスターセッション,第114回日本外科学会定期学術集会)

    高野 奈緒, 中山 吾郎, 薮崎 紀充, 高見 秀樹, 村井 俊文, 岩田 直樹, 神田 光郎, 田中 千恵, 小林 大介, 山田 豪, 藤井 努, 杉本 博行, 小池 聖彦, 野本 周嗣, 藤原 道隆, 小寺 泰弘, 上原 圭介, 安藤 雄一

    日本外科学会雑誌   115 巻 ( 2 ) 頁: 650   2014年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人日本外科学会  

    CiNii Research

  40. Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma

    Shimizu Dai, Kanda Mitsuro, Nomoto Shuji, Oya Hisaharu, Takami Hideki, Hibino Soki, Suenaga Masaya, Inokawa Yoshikuni, Hishida Mitsuhiro, Takano Nao, Nishikawa Yoko, Yamada Suguru, Fujii Tsutomu, Nakayama Goro, Sugimoto Hiroyuki, Koike Masahiko, Fujiwara Michitaka, Kodera Yasuhiro

    ONCOLOGY REPORTS   31 巻 ( 3 ) 頁: 1305 - 1313   2014年3月

     詳細を見る

    記述言語:英語   出版者・発行元:Oncology Reports  

    Patients with hepatocellular carcinoma (HCC) have a poor prognosis, and novel molecular targets for treating recurrence and progression of the disease along with associated biomarkers are urgently required. In the present study, expression and the regulatory mechanism of TUSC1 (tumor suppressor candidate 1) were investigated to determine if it is a candidate tumor suppressor gene for HCC, which shows repressed transcription that involves aberrant DNA methylation. TUSC1 mRNA expression levels in HCC cell lines and 94 pairs of surgical specimens were determined using quantitative real-time reverse transcription polymerase chain reaction assay. Methylation status of HCC cell lines and clinical samples were analyzed to investigate the regulatory mechanism of TUSC1 transcription and the relationship between the methylation status of the TUSC1 gene and clinicopathological factors. The expression and distribution of the TUSC1 protein in liver tissues were determined using immunohistochemistry. A majority of HCC cell lines (89%) and surgical specimens (84%) demonstrated reduced expression levels of TUSC1 mRNA compared with paired non-cancerous liver tissues. The mean mRNA expression level in HCC was significantly lower than in corresponding non-cancerous liver. In contrast, no significant difference was found in TUSC1 mRNA expression level between adjacent normal and cirrhotic liver tissue from HCC patients. The TUSC1 protein expression pattern in HCC and liver tissues was consistent with TUSC1 mRNA expression. Twenty-nine (31%) of 94 patients showed intragenic hypermethylation of the TUSC1 gene in HCC, and hypermethylation was significantly associated with advanced pathological stage. Subsequently, patients with hypermethylation of the TUSC1 gene had a significantly poorer prognosis than patients without hypermethylation. Our results suggest that TUSC1 is a candidate tumor suppressor gene and intragenic hypermethylation is one of the suppressive mechanisms that regulate TUSC1 transcription in HCC. Intragenic methylation of the TUSC1 gene may serve as a novel prognostic marker of HCC.

    DOI: 10.3892/or.2013.2939

    Web of Science

    Scopus

    PubMed

  41. Total pancreatectomy with segmental duodenectomy preserving right gastroepiploic vein

    Hishida M., Nakao A., Hatsuno T., Yano H., Tanaka T., Takano N., Hotta Y., Nakayama H., Kataoka M., Kondo K.

    Hepato-Gastroenterology   58 巻 ( 105 ) 頁: 198 - 201   2011年1月

     詳細を見る

    出版者・発行元:Hepato-Gastroenterology  

    We performed total pancreatectomy with segmental duodenectomy preserving the gastrocolic trunk and right gastroepiploic vein, to prevent gastric venous congestion, for treatment of pancreatic tumor. This is believed to be the first report of such a procedure. The patient was a 58-year-old man with high serum levels of carbohydrate antigen 19-9 and carcinoembryonic antigen. He was examined by abdominal ultrasonography and computed tomography, and diagnosed with cancer of the pancreatic body. No distant metastasis was found. We decided to perform distal pancreatectomy. After surgery, the cut edge of the distal pancreas was subjected to frozen section examination, and there was carcinoma in situ in the stump of the main pancreatic duct. Therefore, we cut the pancreatic head partially, twice, but carcinoma in situ remained. We additionally performed pancreatic head resection with segmental duodenectomy, with preservation of the gastroduodenal artery, right gastroepiploic artery, gastrocolic trunk and right gastroepiploic vein to prevent gastric venous congestion. The postoperative course was uneventful and the patient remains in good condition. This surgical technique is considered feasible and safe for prevention of gastric venous congestion. © H.G.E. Update Medical Publishing S.A.

    Scopus

  42. Total pancreatectomy with segmental duodenectomy preserving right gastroepiploic vein.

    Hishida M, Nakao A, Hatsuno T, Yano H, Tanaka T, Takano N, Hotta Y, Nakayama H, Kataoka M, Kondo K

    Hepato-gastroenterology   58 巻 ( 105 ) 頁: 198 - 201   2011年1月

     詳細を見る

    記述言語:英語  

    PubMed

  43. Total Pancreatectomy with Segmental Duodenectomy Preserving Right Gastroepiploic Vein

    Hishida Mitsuhiro, Nakao Akimasa, Hatsuno Tsuyoshi, Yano Hiromasa, Tanaka Teruyoshi, Takano Nao, Hotta Yoshihiro, Nakayama Hiroshi, Kataoka Masato, Kondo Ken

    HEPATO-GASTROENTEROLOGY   58 巻 ( 105 ) 頁: 198 - 201   2011年

     詳細を見る

  44. 術前および再発時にEP療法(etoposide+cisplatin)を行い奏効した副腎皮質癌の1例

    大島 由記子, 高野 奈緒, 加藤 彩, 林 孝子, 近藤 建, 佐藤 康幸

    日本臨床外科学会雑誌   69 巻 ( 3 ) 頁: 671 - 675   2008年

     詳細を見る

    記述言語:日本語   出版者・発行元:日本臨床外科学会  

    副腎皮質癌の予後は悪く,進行および再発時の治療法としては確立されたものがないのが現状である.今回われわれは副腎皮質癌に対して化学療法を行い治療効果のみられた症例を経験したので報告する.<BR>症例は29歳,女性.17歳時悪性リンパ腫にて化学療法施行し寛解.27歳時発熱が続き検査施行したところ,CTにて後腹膜腫瘍を認め当院紹介となった.術前には確定診断がつかず,開腹手術施行.手術時生検結果で未分化癌と診断され切除せず術後EP療法を行っていたが,化学療法中に副腎皮質癌の診断となったため3クール施行しその後副腎腫瘍摘出術施行.経過観察中の術後1年4カ月後のCTにて腹膜腫瘤を認め,副腎皮質癌の腹膜再発と診断し再度EP療法を施行.8クール終了時のCTでは腹膜の腫瘤は画像上縮小しており,化学療法の効果が認められた.

    DOI: 10.3919/jjsa.69.671

    CiNii Research

▼全件表示

科研費 1

  1. 消化器外科手術切除断端へのRapid QMSP法の応用

    研究課題/研究課題番号:15K19850  2015年4月 - 2017年3月

    科学研究費助成事業  若手研究(B)

    高野 奈緒, 林 真路, 栗本 景介, 神田 光郎

      詳細を見る

    担当区分:研究代表者 

    配分額:4030000円 ( 直接経費:3100000円 、 間接経費:930000円 )

    ある組織が癌か否かを知るためには、癌特異的な遺伝子異常がそこにあるかどうかを知ることで判断できる。遺伝子異常を調べるためには通常日単位の時間が必要であるが、我々は所要時間2時間半で、安価に、再現性をもって診断する手法を確立した。その迅速性は日常臨床でも生かせる可能性があり、特に外科的切除を行う際に、切除断端に癌の遺残がないかどうかを術中に診断できる。今後種々のキットや測定機械の開発により、さらなる時間短縮が図れる可能性があると考えている。